Anti-hepatitis B virus activities of triterpenoid saponin compound from Potentilla anserine L

被引：97

作者：

Zhao, Y. -L. ^{[1
,2
]}

Cai, G. -M. ^{[1
]}

Hong, X. ^{[1
]}

Shan, L. -M. ^{[1
]}

Xiao, X. -H. ^{[1
]}

机构：

[1] Peoples Liberat Army, Inst Tradit Chinese Mat Med, Beijing 100039, Peoples R China

[2] Acad Mil Med Sci, Beijing 100039, Peoples R China

来源：

PHYTOMEDICINE | 2008年 / 15卷 / 04期

关键词：

triterpenoid saponin (TS); HBV; 2.2.15; cells; Peking duckling;

D O I：

10.1016/j.phymed.2008.01.005

中图分类号：

Q94 [植物学];

学科分类号：

071001 ;

摘要：

The Tibetan herb Potentilla anserina L. has been widely used in China for many thousands of years to treat hepatitis-B. Bioassay-guided fractionation of the ethanol extract of the rhizomes led to the isolation of a triterpenoid saponin (TS) that was determined to be 2 alpha,3 beta,19 alpha-trihydroxyurs-12-en-28-oic acid beta-D-glucopyranosyl ester. Using models of HBV infection, this compound was evaluated for its effect on HBV antigene expression in the 2.2.15 cell line in vitro and anti-hepatitis B virus (HBV) activities in Peking ducklings in vivo. Results showed that it could decrease the expression levels of HBsAg, HBeAg and HBVDNA in the 2.2.15 cell culture and the inhibitory effect was not due to the cytotoxity of the triterpenoid saponin. The antiviral study in vivo on Peking ducklings also demonstrated that this compound inhibits duck hepatitis B virus (DHBV) DNA replication. (C) 2008 Elsevier GmbH. All rights reserved.

引用

页码：253 / 258

页数：6

共 28 条

[1] A Review of Natural and Modified Betulinic, Ursolic and Echinocystic Acid Derivatives as Potential Antitumor and Anti-HIV Agents [J].

Baglin, I. ;

Mitaine-Offer, A. -C. ;

Nour, M. ;

Tan, K. ;

Cave, C. ;

Lacaille-Dubois, M. -A. .

MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2003, 3 (06) :525-539

[2]

Chen H., 2000, J CHIM MAT MED, V25, P311

[3]

Cova Lucyna, 2004, Methods Mol Med, V96, P261

[4]

Dang SS, 2006, MED SCI MONITOR, V12, pBR302

[5]

Gumina Giuseppe, 2002, Current Topics in Medicinal Chemistry, V2, P1065, DOI 10.2174/1568026023393138

[6]

Hanazaki Kazuhiro, 2004, Current Drug Targets - Inflammation and Allergy, V3, P63, DOI 10.2174/1568010043483908

[7]

Hantz Olivier, 2004, Methods Mol Med, V96, P189

[8] HEPATITIS-B REACTIVATION AFTER LAMIVUDINE [J].

HONKOOP, P ;

DEMAN, RA ;

HEIJTINK, RA ;

SCHALM, SW .

LANCET, 1995, 346 (8983) :1156-1157

[9] Lamivudine resistance in immunocompetent chronic hepatitis B - Incidence and patterns [J].

Honkoop, P ;

Niesters, HGM ;

deMan, RAM ;

Osterhaus, ADME ;

Schalm, SW .

JOURNAL OF HEPATOLOGY, 1997, 26 (06) :1393-1395

[10]

Kann Michael, 2004, Hepatology, V39, P838, DOI 10.1002/hep.20144

← 1 2 3 →